Diabetes mellitus and cardiovascular prevention: The role and the limitations of currently available antiplatelet drugs

International Journal of Vascular Medicine

Volumn 2011, Issue , 2011, Pages

  Tufano, A ^a   Cimino, E ^a   Di Minno, M N D ^a   Ierano P ^a   Marrone, E ^a   Strazzullo, A ^a   Di Minno, G ^a   Cerbone, A M ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884395392     PISSN: 20902824     EISSN: 20902832     Source Type: Journal    
DOI: 10.1155/2011/250518     Document Type: Review

References (51)

1. Nesto R. W., Correlation between cardiovascular disease and diabetes mellitus: current concepts. American Journal of Medicine 2004 116 supplement 5 11S 22S 2-s2.0-1542513468 10.1016/j.amjmed.2003.10.016
2. Ferroni P., Basili S., Falco A., Davi G., Platelet activation in type 2 diabetes mellitus. Journal of Thrombosis and Haemostasis 2004 2 8 1282 1291 2-s2.0-13244274961 10.1111/j.1538-7836.2004.00836.x
3. Tschoepe D., Roesen P., Schwippert B., Gries F. A., Platelets in diabetes: the role in the hemostatic regulation in atherosclerosis. Seminars in Thrombosis and Hemostasis 1993 19 2 122 128 2-s2.0-0027230928
4. Demirtunc R., Duman D., Basar M., Bilgi M., Teomete M., Garip T., The relationship between glycemic control and platelet activity in type 2 diabetes mellitus. Journal of Diabetes and Its Complications 2009 23 2 89 94 2-s2.0-59849109177 10.1016/j.jdiacomp.2008.01.006
5. Winocour P. D., Platelets, vascular disease, and diabetes mellitus. Canadian Journal of Physiology and Pharmacology 1994 72 3 295 303 2-s2.0-0028332290
6. Bridges J. M., Dalby A. M., Millar J. H. D., Weaver J. A., An effect of d-glucose on platelet stickiness. The Lancet 1965 285 7376 75 77 2-s2.0-0037804950
7. Colwell J. A., Nesto R. W., The platelets in diabetes: focus on prevention of ischemic events. Diabetes Care 2003 26 7 2181 2188 2-s2.0-0346858009
8. Watala C., Boncler M., Gresner P., Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus. Pharmacological Reports 2005 57 42 58 2-s2.0-33645678090
9. Angiolillo D. J., Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care 2009 32 4 531 540 2-s2.0-65349185008 10.2337/dc08-2064
10. Antithrombotic Trialists' (ATT) Collaboration, Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. The Lancet 2009 373 9678 1849 1860 2-s2.0-65849268320 10.1016/S0140-6736(09)60503-1
11. Buse J. B., Ginsberg H. N., Bakris G. L., Clark N. G., Costa F., Eckel R., Fonseca V., Gerstein H. C., Grundy S., Nesto R. W., Pignone M. P., Plutzky J., Porte D., Redberg R., Stitzel K. F., Stone N. J., Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007 115 1 114 126 2-s2.0-33846083971 10.1161/CIRCULATIONAHA.106. 179294
12. Buse J. B., Ginsberg H. N., Bakris G. L., Clark N. G., Costa F., Eckel R., Fonseca V., Gerstein H. C., Grundy S., Nesto R. W., Pignone M. P., Plutzky J., Porte D., Redberg R., Stitzel K. F., Stone N. J., Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007 30 1 162 172 2-s2.0-33846025092 10.2337/dc07-9917
13. Pearson T. A., Blair S. N., Daniels S. R., Eckel R. H., Fair J. M., Fortmann S. P., AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases (AHA scientific statement). Circulation 2002 106 3 388 391 10.1161/01.CIR. 0000020190.45892.75
14. Ryden L., Standl E., Bartnik M., Van Den Berghe G., Betteridge J., De Boer M. J., Cosentino F., Jönsson B., Laakso M., Malmberg K., Priori S., Östergren J., Tuomilehto J., Thrainsdottir I., Vanhorebeek I., Stramba-Badiale M., Lindgren P., Qiao Q., Blanc J. J., Budaj A., Camm J., Dean V., Deckers J., Dickstein K., Lekakis J., McGregor K., Metra M., Morais J., Osterspey A., Tamargo J., Zamorano J. L., Deckers J. W., Bertrand M., Charbonnel B., Erdmann E., Ferrannini E., Flyvbjerg A., Gohlke H., Juanatey J. R. G., Graham I., Monteiro P. F., Parhofer K., Pyörälä K., Raz I., Schernthaner G., Volpe M., Wood D., Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal 2007 28 1 88 136 2-s2.0-33846414720 10.1093/eurheartj/ehl260
15. Ogawa H., Nakayama M., Morimoto T., Uemura S., Kanauchi M., Doi N., Jinnouchi H., Sugiyama S., Saito Y., Low-dose Aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. Journal of the American Medical Association 2008 300 18 2134 2141 2-s2.0-56149113603 10.1001/jama.2008.623
16. Belch J., MacCuish A., Campbell I., Cobbe S., Taylor R., Prescott R., Lee R., Bancroft J., MacEwan S., Shepherd J., Macfarlane P., Morris A., Jung R., Kelly C., Connacher A., Peden N., Jamieson A., Matthews D., Leese G., McKnight J., O'Brien I., Semple C., Petrie J., Gordon D., Pringle S., MacWalter R., The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of Aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. British Medical Journal 2008 337, article a1840 2-s2.0-54949131747
17. De Berardis G., Sacco M., Strippoli G. F. M., Pellegrini F., Graziano G., Tognoni G., Nicolucci A., Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. British Medical Journal 2009 339, article b4531 2-s2.0-71749105108 10.1136/bmj.b4531
18. Nicolucci A., De Berardis G., Sacco M., Tognoni G., AHA/ADA vs. ESC/EASD recommendations on Aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions. European Heart Journal 2007 28 16 1925 1927 2-s2.0-35348908027 10.1093/eurheartj/ehm248
19. Colwell J. A., Diabetes: does Aspirin use reduce cardiovascular risk in diabetes? Nature Reviews Endocrinology 2009 5 4 188 190 2-s2.0-67649362165 10.1038/nrendo.2009.44
20. Pignone M., Alberts M. J., Colwell J. A., Cushman M., Inzucchi S. E., Mukherjee D., Rosenson R. S., Williams C. D., Wilson P. W., Kirkman M. S., Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation 2010 121 24 2694 2701 2-s2.0-77954087762 10.1161/CIR.0b013e3181e3b133
21. American Diabetes Association, Aspirin therapy in diabetes (position statement). Diabetes Care 2004 27 supplement 1 S72 S73
22. Altman R., Carreras L., Diaz R., Collaborative overview of randomised trials of antiplatelet therapy-I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. British Medical Journal 1994 308 6921 81 106
23. Antithrombotic Trialist's Collaboration, Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. British Medical Journal 2002 324 7329 71 86
24. Watala C., Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus. Current Pharmaceutical Design 2005 11 18 2331 2365 2-s2.0-21044457137 10.2174/1381612054367337
25. Gent M., A randomised, blinded, trial of clopidogrel versus Aspirin in patients at risk of ischaemic events (CAPRIE). The Lancet 1996 348 9038 1329 1339 2-s2.0-0030590746 10.1016/S0140-6736(96)09457-3
26. Bhatt D. L., Marso S. P., Hirsch A. T., Ringleb P. A., Hacke W., Topol E. J., Amplified benefit of Clopidogrel versus Aspirin in patients with diabetes mellitus. American Journal of Cardiology 2002 90 6 625 628 2-s2.0-0037106972 10.1016/S0002-9149(02)02567-5
27. Yusuf S., Zhao F., Mehta S. R., Chrolavicius S., Tognoni G., Fox K. K., Effects of clopidogrel in addition to Aspirin in patients with acute coronary syndromes without ST-segment elevation. New England Journal of Medicine 2001 345 7 494 502 10.1056/NEJMoa010746
28. Anderson J. L., Adams C. D., Antman E. M., ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 2002 Guidelines for the management of Patients with Unstable angina/ non-ST-elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiographyand Interventions, and the Society of Thoracis Surgeons endorsed by the Amrican Association of cardiovascular and pulmonary Rehabilitation and the Society for Academic Emergency medicine. Journal of the American College of Cardiology 2007 50 7 e1 e157
29. Gasparyan A. Y., Watson T., Lip G. Y. H., The role of Aspirin in cardiovascular prevention: implications of Aspirin resistance. Journal of the American College of Cardiology 2008 51 19 1829 1843 2-s2.0-42949165089 10.1016/j.jacc.2007.11.080
30. Sanderson S., Emery J., Baglin T., Kinmonth A. L., Narrative review: Aspirin resistance and its clinical implications. Annals of Internal Medicine 2005 142 5 370 380 2-s2.0-14344262368
31. Angiolillo D. J., Antiplatelet therapy in type 2 diabetes mellitus. Current Opinion in Endocrinology, Diabetes and Obesity 2007 14 2 124 131 2-s2.0-33847668393 10.1097/MED.0b013e32807f2ad9
32. Watala C., Pluta J., Golanski J., Rozalski M., Czyz M., Trojanowski Z., Drzewoski J., Increased protein glycation in diabetes mellitus is associated with decreased Aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to Aspirin. Journal of Molecular Medicine 2005 83 2 148 158 2-s2.0-15044348667 10.1007/s00109-004-0600-x
33. Di Minno G., Violi F., Aspirin resistance and diabetic angiopathy: back to the future. Thrombosis Research 2004 113 2 97 99 2-s2.0-2042449119 10.1016/j.thromres.2004.02.017
34. Ajjan R., Storey R. F., Grant P. J., Aspirin resistance and diabetes mellitus. Diabetologia 2008 51 3 385 390 2-s2.0-39049101880 10.1007/s00125-007- 0898-3
35. Cerbone A. M., MacArone-Palmieri N., Saldalamacchia G., Coppola A., Di Minno G., Rivellese A. A., Diabetes, vascular complications and antiplatelet therapy: open problems. Acta Diabetologica 2009 46 4 253 261 2-s2.0-70449523675 10.1007/s00592-008-0079-y
36. Geisler T., Anders N., Paterok M., Langer H., Stellos K., Lindemann S., Herdeg C., May A. E., Gawaz M., Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 2007 30 2 372 374 2-s2.0-33846656039 10.2337/dc06-1625
37. Angiolillo D. J., Fernandez-Ortiz A., Bernardo E., Ramírez C., Sabaté M., Jimenez-Quevedo P., Hernández R., Moreno R., Escaned J., Alfonso F., Bañuelos C., Costa M. A., Bass T. A., Macaya C., Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined Aspirin and clopidogrel treatment. Diabetes 2005 54 8 2430 2435 2-s2.0-23644433510 10.2337/diabetes.54.8.2430
38. Ferreira I. A., Mocking A. I., Feijge M. A., Gorter G., Van Haeften T. W., Heemskerk J. W. M., Akkerman J. W. N., Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 2 417 422 2-s2.0-33644870179 10.1161/01.ATV.0000199519.37089.a0
39. Colwell J. A., Is Aspirin effective in diabetic patients? Yes. Journal of Thrombosis and Haemostasis 2005 3 12 2612 2614 2-s2.0-29244491679 10.1111/j.1538-7836.2005.01719.x
40. Cimminiello C., Is Aspirin effective in diabetic patients? No. Journal of Thrombosis and Haemostasis 2005 3 12 2615 2616 2-s2.0-29244485586 10.1111/j.1538-7836.2005.01720.x
41. Campbell C. L., Smyth S., Montalescot G., Steinhubl S. R., Aspirin dose for the prevention of cardiovascular disease: a systematic review. Journal of the American Medical Association 2007 297 18 2018 2024 2-s2.0-34248352504 10.1001/jama.297.18.2018
42. Michelson A. D., Cattaneo M., Eikelboom J. W., Gurbel P., Kottke-Marchant K., Kunicki T. J., Pulcinelli F. M., Cerletti C., Rao A. K., Aspirin resistance: position paper of the working group on Aspirin resistance. Journal of Thrombosis and Haemostasis 2005 3 6 1309 1311 2-s2.0-24944474901 10.1111/j.1538-7836.2005.01351.x
43. Davì G., Santilli F., Aspirin as antiplatelet agent in diabetes. PROS-. European Journal of Internal Medicine 2010 21 3 149 153 2-s2.0-77952290056 10.1016/j.ejim.2010.03.008
44. Patrono C., Rocca B., The future of antiplatelet therapy in cardiovascular disease. Annual Review of Medicine 2010 61 49 61 2-s2.0-77951920964 10.1146/annurev-med-020209-171035
45. Di Minno G., Silver M. J., Cerbone A. M., Murphy S., Trial of repeated low-dose Aspirin in diabetic angiopathy. Blood 1986 68 4 886 891 2-s2.0-0022970057
46. Wong S., Morel-Kopp M. C., Chen Q., Appleberg M., Ward C. M., Lewis D. R., Overcoming Aspirin resistance: increased platelet inhibition with combination Aspirin and clopidogrel and high dose Aspirin therapy in Aspirin resistant patients with peripheral vascular disease. Thrombosis and Haemostasis 2006 95 6 1042 1043 2-s2.0-33745325634 10.1160/TH05-12-0808
47. Angiolillo D. J., Capranzano P., Goto S., Aslam M., Desai B., Charlton R. K., Suzuki Y., Box L. C., Shoemaker S. B., Zenni M. M., Guzman L. A., Bass T. A., A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. European Heart Journal 2008 29 18 2202 2211 2-s2.0-52449085759 10.1093/eurheartj/ehn287
48. King S. B., Smith S. C., Hirshfeld J. W., Jacobs A. K., Morrison D. A., Williams D. O., 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Journal of the American College of Cardiology 2008 51 2 172 209 2-s2.0-38349076614 10.1016/j.jacc.2007.10.002
49. Angiolillo D. J., Shoemaker S. B., Desai B., Yuan H., Charlton R. K., Bernardo E., Zenni M. M., Guzman L. A., Bass T. A., Costa M. A., A randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the optimizing antiplatelet therapy in diabetes mellitus (OPTIMUS) study. Circulation 2007 115 6 708 716 2-s2.0-33847130538
50. Wiviott S. D., Braunwald E., Angiolillo D. J., Meisel S., Dalby A. J., Verheugt F. W. A., Goodman S. G., Corbalan R., Purdy D. A., Murphy S. A., McCabe C. H., Antman E. M., Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation 2008 118 16 1626 1636 2-s2.0-55949103494 10.1161/CIRCULATIONAHA.108.791061
51. Neri Serneri G. G., Coccheri S., Marubini E., Violi F., Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. European Heart Journal 2004 25 20 1845 1852 10.1016/j.ehj.2004.07.013